Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial
- 30 April 2006
- journal article
- research article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 8-12
- https://doi.org/10.1053/j.seminoncol.2006.03.025
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Prevention of Hormone-Related Cancers: Breast CancerJournal of Clinical Oncology, 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002Journal of Clinical Oncology, 2002
- Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over StudyJournal of Clinical Oncology, 2002
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI Journal of the National Cancer Institute, 2001
- Aromatase inhibitors and their antitumor effects in model systems.Endocrine-Related Cancer, 1999
- The effects of aromatase inhibitors and antiestrogens in the nude mouse modelBreast Cancer Research and Treatment, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998